Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Bolsa de valores de Sao Paulo  >  Fleury SA    FLRY3   BRFLRYACNOR5

FLEURY SA (FLRY3)
Mes dernières consult.
Most popular
  Report  
End-of-day quote. End-of-day quote  - 04/21
27.3 BRL   --.--%
04/12MATERIAL FACT : Fourth Issue of Debentures
PU
01/29NOTICE TO THE M : Change in management
PU
2017FLEURY : Payment of Interest on Shareholders’ Equity
PU
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Material Fact: Fourth Issue of Debentures

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/12/2018 | 10:57pm CEST

FLEURY S.A.

Public Company

Corporate Taxpayer ID (CNPJ/MF) 60.840.055/0001-31

Company Registry (NIRE) 35 3 00197534

Material Fact

Fourth Issue of Debentures

São Paulo, April 12th 2018 - Grupo Fleury S.A. ("Company"), in compliance with CVM´s Instruction 358 of January 3rd, 2002, as amended, informs to its shareholders and the market in general that, in this date, the Company's Board of Directors approved the fourth issue of ordinary debentures, not convertible into shares, unsecured and in two series ("Debentures") for public distribution with restricted placement efforts, pursuant to CVM's Instruction 476 of January 16th, 2009, as amended ("CVM's Instruction 476" and "Restricted Offer", respectively).

The Restricted Offer will consist in the issuance by the Company of 25,000 (twenty-five thousand) Debentures of the first series ("First Series Debentures") and 25,000 (twenty-five thousand) Debentures of the second series ("Second Series Debentures"), totaling 50,000 (fifty thousand) debentures all nominative, book-entry and with unit face value of R$10,000.00 (ten thousand Reais) ("Unit Face Value"), therefore the amount of each series consisting of R$ 250,000,000.00 (two hundred and fifty million Reais), totaling, in the issuance date of the Debentures, as of April 27th 2018 ("Issuance Date"), R$ 500,000,000.00 (five hundred million Reais). The maturity period of the First Series Debentures will be 3 (three) years and the maturity period of the Second Series Debentures will be 5 (five) years, both of them counting from the Issuance Date, subject to the terms to be set forth in the "Deed Private Instrument of the fourth Issuance of Ordinary Debentures, Not convertible into shares, in Two Series, Unsecured Type, for Public Distribution with Restricted Distribution Efforts, of Fleury S.A." ("Issuance Deed").

The Debentures will be fully amortized in single installments on the respective maturity dates, with the Debentures of the First Series being settled on April 27th, 2021 and the Debentures of the Second Series settled on April 27th, 2023.

The Debentures will be entitled to payment corresponding to 100% (one hundred percent) of the accumulated variation of the average daily rate of DI - Daily interbank deposit rates, "over extra group", expressed in percentage per year, 252 (two hundred and two) working days basis, plus a spread of (i) 0.35% (thirty-five hundredths per cent) per year, basis 252 (two hundred and fifty-two) working days for the First Series Debentures; and (ii) 0.60% (sixtieths hundredths per cent) per year, basis 252 (two hundred and fifty-two) working days for the Second Series Debentures.

The net resources raised by the Company through the Restricted Offer will be used to reinforce Company's cash position.

This document is for information purpose, in accordance with the legislation, and must not be interpreted as a document of Debenture's sales.

More information on the Restricted Offer can be obtained in the minutes of the meeting of the board of directors and in the Deed Private Instrument of the Fourth Issuance of Ordinary Debentures, available on the CVM website (www.cvm.gov.br) or on the investor relations website (www.fleury.com.br/ri).

Viviane Behar de Castro

Investor Relations Officer

Disclaimer

Fleury SA published this content on 12 April 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 12 April 2018 20:56:28 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FLEURY SA
04/12MATERIAL FACT : Fourth Issue of Debentures
PU
01/29NOTICE TO THE MARKET : Change in management
PU
2017FLEURY : Payment of Interest on Shareholders’ Equity
PU
2017MATERIAL FACT : Third Issue of Debentures
PU
2017NOTICE TO THE MARKET : Change in management
PU
2017NOTICE TO THE MARKET : resignation of members of the Board of Directors
PU
2017MATERIAL FACT : shares sale by a signatory of the Company´s shareholders´ agreem..
PU
2017NOTICE TO THE MARKET : Public Civil Action
PU
2017FLEURY : Call Notice to General Extraordinary Shareholders’ Meeting
PU
2017NOTICE TO THE MARKET : change in management
PU
More news
News from SeekingAlpha
03/05Fleury SA 2017 Q4 - Results - Earnings Call Slides 
2017Fleury SA 2017 Q3 - Results - Earnings Call Slides 
Financials ( BRL)
Sales 2018 2 700 M
EBIT 2018 538 M
Net income 2018 366 M
Debt 2018 307 M
Yield 2018 2,10%
P/E ratio 2018 22,12
P/E ratio 2019 19,00
EV / Sales 2018 3,30x
EV / Sales 2019 2,95x
Capitalization 8 608 M
Chart FLEURY SA
Duration : Period :
Fleury SA Technical Analysis Chart | FLRY3 | BRFLRYACNOR5 | 4-Traders
Technical analysis trends FLEURY SA
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 31,3  BRL
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Carlos Alberto Iwata Marinelli Chief Executive Officer
Marcos Bosi Ferraz Chairman
Fernando Augusto Rodrigues Leão Filho Chief Financial & Legal Officer
Edgar Gil Rizzatti Head-Medical, Technical & Process
Samuel Monteiro dos Santos Director
Sector and Competitors
1st jan.Capitalization (M$)
FLEURY SA-5.22%2 526
SONIC HEALTHCARE LIMITED0.96%7 517
BML INC-2.96%1 125
DR. LAL PATHLABS LTD-3.97%1 065
INSTITUTO HERMES PARDINI SA-17.07%1 065
NEOGENOMICS, INC.4.63%746